Trial Profile
Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2019
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Gimeracil/oteracil/tegafur; Levofolinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 02 Jun 2017 Results assessing the association between the neutrophil-lymphocyte ratio and clinical outcome (n=71), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 09 May 2013 New trial record